Modifying PEST for Psoriatic Arthritis Screening

Launched by NOVARTIS PHARMACEUTICALS · Apr 19, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how adding two new questions and some pictures to an existing screening tool called PEST can help better identify people with psoriatic arthritis (PsA) who also have moderate-to-severe plaque psoriasis (a skin condition). The goal is to see if these additions improve the chances of correctly diagnosing PsA in patients living in Canada.

To participate in this study, you need to be an adult with moderate-to-severe plaque psoriasis and meet certain health criteria. Importantly, you should not have already been diagnosed with PsA or any other type of inflammatory arthritis, and you should not have been treated with specific medications for this condition. If you join, you can expect to answer some questions and share your experiences regarding your skin condition. The trial is currently recruiting participants of all genders, so if you think you might qualify, it could be a great opportunity to help improve the understanding of PsA screening.

Gender

ALL

Eligibility criteria

• Key inclusion criteria:
• • 1. Moderate-to-severe plaque PsO patients who are candidates for bDMARDs, as per provincial reimbursement criteria
• • 2. Adult patients at the time of informed consent signature
• • 3. Patients able to understand and willing to comply with protocol requirements, instructions, and restrictions
• • 4. Residents of Canada
• Key exclusion criteria:
• • 1. Patients who have previously screened positive for PsA through PEST or any other screening method
• • 2. Patients who have been diagnosed with PsA and/or followed by a rheumatologist
• • 3. Patients who have been diagnosed with inflammatory arthritis unrelated to PsA (rheumatoid arthritis, reactive arthritis, enteropathic arthritis, axial spondyloarthritis)
• • 4. Patients treated with a bDMARD for moderate-to-severe plaque PsO or any other medical condition